Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial.
Julie EgeaJulia SalleronSophie GourgouAhmet AyavValérie LaurentBéata JuzynaAlexandre HarléThierry ConroyAurélien LambertPublished in: Cancers (2022)
The self-assessment of patients' general health status alongside tumor markers is an interesting approach to the diagnosis of the tumor progression of metastatic pancreatic cancer patients during first-line treatment.